Systematic review and network meta-analysis of biologics and small molecules for scalp psoriasis - PubMed
3 days ago
- #network meta-analysis
- #scalp psoriasis
- #biologics
- The systematic review and network meta-analysis evaluates the efficacy, safety, and tolerability of biologics and small molecules for treating scalp psoriasis.
- A total of 16 randomized controlled trials including 10,266 patients were analyzed, with primary outcomes measured at Weeks 12-16.
- Ixekizumab and brodalumab ranked highest for scalp clearance, while guselkumab showed a favorable balance of efficacy and safety.
- Several agents, including secukinumab and apremilast, were associated with higher incidences of all-grade adverse events compared to placebo.
- Apremilast was the only agent with significantly higher discontinuation rates due to adverse events, and no significant increase in serious adverse events was found across treatments.